Literature DB >> 30083834

Downstaging with Localized Concurrent Chemoradiotherapy Can Identify Optimal Surgical Candidates in Hepatocellular Carcinoma with Portal Vein Tumor Thrombus.

Jae Uk Chong1, Gi Hong Choi1, Dai Hoon Han1, Kyung Sik Kim1, Jinsil Seong2, Kwang-Hyub Han3, Jin Sub Choi4.   

Abstract

BACKGROUND: Locally advanced hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT) has a poor oncological outcome. This study evaluated the oncological outcomes and prognostic factors of surgical resection after downstaging with localized concurrent chemoradiotherapy (CCRT) followed by hepatic arterial infusion chemotherapy (HAIC).
METHODS: From 2005 to 2014, 354 patients with locally advanced HCC underwent CCRT followed by HAIC. Among these patients, 149 patients with PVTT were analyzed. Exclusion criteria included a total bilirubin ≥ 2 mg/dL, platelet count < 100,000/μL, and indocyanine green retention test (ICG R15) > 20%. During the same study period, 18 patients with PVTT underwent surgical resection as the first treatment. Clinicopathological characteristics and oncological outcomes between groups were compared.
RESULTS: Among 98 patients in the CCRT group, 26 patients (26.5%) underwent subsequent curative resection. The median follow-up period was 13 months (range 1-131 months). Disease-specific survival differed significantly between the resection after localized CCRT group and the resection-first group {median 62 months (95% confidence interval [CI] 22.99-101.01) versus 15 months (95% CI 10.84-19.16), respectively; P = 0.006}. Multivariate analyses showed that achievement of radiologic response was an independently good prognostic factor for both disease-specific survival (P = 0.039) and disease-free survival (P = 0.001)
CONCLUSIONS: Localized CCRT could be an effective tool for identifying optimal candidates for surgical treatment with favorable tumor biology. Furthermore, with a 26.5% resection rate and 100% response in PVTT for resection after CCRT, our localized CCRT protocol may be ideal for PVTT.

Entities:  

Mesh:

Year:  2018        PMID: 30083834     DOI: 10.1245/s10434-018-6653-9

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  12 in total

1.  Biomarkers for Locally Advanced Hepatocellular Carcinoma Patients Treated with Liver-Directed Combined Radiotherapy.

Authors:  Seung Yeun Chung; Kyoung-Jin Kim; Jinsil Seong
Journal:  Liver Cancer       Date:  2022-01-24       Impact factor: 12.430

2.  Guidelines for Diagnosis and Treatment of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus in China (2021 Edition).

Authors:  Juxian Sun; Rongping Guo; Xinyu Bi; Mengchao Wu; Zhaoyou Tang; Wan Yee Lau; Shusen Zheng; Xuehao Wang; Jinming Yu; Xiaoping Chen; Jia Fan; Jiahong Dong; Yongjun Chen; Yunfu Cui; Chaoliu Dai; Chihua Fang; Shuang Feng; Zhili Ji; Weidong Jia; Ningyang Jia; Gong Li; Jing Li; Qiu Li; Jiangtao Li; Tingbo Liang; Lianxin Liu; Shichun Lu; Yi Lv; Yilei Mao; Yan Meng; Zhiqiang Meng; Feng Shen; Jie Shi; Huichuan Sun; Kaishan Tao; Gaojun Teng; Xuying Wan; Tianfu Wen; Liqun Wu; Jinglin Xia; Mingang Ying; Jian Zhai; Leida Zhang; Xuewen Zhang; Zhiwei Zhang; Haiping Zhao; Donghai Zheng; Xuting Zhi; Jie Zhou; Cuncai Zhou; Jian Zhou; Zhaochong Zeng; Kangshun Zhu; Minshan Chen; Jianqiang Cai; Shuqun Cheng
Journal:  Liver Cancer       Date:  2022-03-17       Impact factor: 12.430

3.  Liver-Directed Concurrent Chemoradiotherapy versus Sorafenib in Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis.

Authors:  Jina Kim; Hwa Kyung Byun; Tae Hyung Kim; Sun Il Kim; Beom Kyung Kim; Seung Up Kim; Jun Yong Park; Do Young Kim; Jinsil Seong
Journal:  Cancers (Basel)       Date:  2022-05-12       Impact factor: 6.575

4.  Role and limitation of neoadjuvant hepatic arterial infusion chemotherapy in advanced hepatocelluar carcinoma patients with Child-Pugh class A.

Authors:  Beom-Hui Lee; Dong-Shik Lee; Chan Woo Cho; Sung-Su Yun
Journal:  World J Surg Oncol       Date:  2019-08-15       Impact factor: 2.754

5.  Appraisal of Long-Term Outcomes of Liver-Directed Concurrent Chemoradiotherapy for Hepatocellular Carcinoma with Major Portal Vein Invasion.

Authors:  Dai Hoon Han; Beom Kyung Kim; Sojung Han; Hye Won Lee; Jun Yong Park; Seung Up Kim; Do Young Kim; Sang Hoon Ahn; Kwang-Hyub Han; Jinsil Seong; Jong Yun Won
Journal:  J Hepatocell Carcinoma       Date:  2020-12-17

Review 6.  Neoadjuvant treatment strategies for hepatocellular carcinoma.

Authors:  Lei Xu; Lin Chen; Wei Zhang
Journal:  World J Gastrointest Surg       Date:  2021-12-27

7.  A Prospective Study of Liver Regeneration After Radiotherapy Based on a New (Su'S) Target Area Delineation.

Authors:  Ting-Shi Su; Li-Qing Li; Shi-Xiong Liang; Bang-De Xiang; Jian-Xu Li; Jia-Zhou Ye; Le-Qun Li
Journal:  Front Oncol       Date:  2021-08-26       Impact factor: 6.244

Review 8.  Will the collaboration of surgery and external radiotherapy open new avenues for hepatocellular carcinoma with portal vein thrombosis?

Authors:  Jung Wan Choe; Hye Yoon Lee; Chai Hong Rim
Journal:  World J Gastroenterol       Date:  2022-02-21       Impact factor: 5.742

Review 9.  Chinese expert consensus on neoadjuvant and conversion therapies for hepatocellular carcinoma.

Authors:  Hai-Tao Zhao; Jian-Qiang Cai
Journal:  World J Gastroenterol       Date:  2021-12-21       Impact factor: 5.742

10.  Sorafenib with or without concurrent transarterial chemoembolization in hepatocellular carcinoma: a cautionary comment of STAH trial.

Authors:  Jia-Hao Chen; Xu Liu; Kang Chen; Xiao-Yin Hu; Bang-De Xiang; Wei-Ping Yuan
Journal:  Transl Cancer Res       Date:  2020-01       Impact factor: 1.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.